TIDMAZN
RNS Number : 6170X
AstraZeneca PLC
20 December 2019
20 December 2019 07:00 GMT
AstraZeneca divests rights to Arimidex and Casodex
in Europe and certain additional countries
Sale to Juvisé Pharmaceuticals supports AstraZeneca's
strategy
of focusing on pipeline of new medicines
AstraZeneca today announced that it has agreed to sell the
commercial rights to Arimidex (anastrozole) and Casodex
(bicalutamide) in a number of European, African and other
countries(1) to Juvisé Pharmaceuticals.
The medicines, used primarily to treat breast and prostate
cancers, have lost their compound patent protection in these
countries. AstraZeneca already divested the rights to both Arimidex
and Casodex in the US in 2017.
Dave Fredrickson, Executive Vice President, Oncology Business
Unit, said: "Arimidex and Casodex are important established
medicines and we are pleased that Juvisé Pharmaceuticals will now
take on the work of making sure patients continue to have access to
them. Today's agreement is part of a broader strategy of reducing
our portfolio of mature medicines to reallocate resources towards
developing our pipeline of new medicines."
Financial considerations
As there were no closing conditions to the divestment, the
agreement became effective upon signing. Juvisé Pharmaceuticals has
made an upfront payment of $181m to AstraZeneca and may also make
future sales-contingent payments of up to $17m. Income arising from
the upfront payment will be reported in AstraZeneca's financial
statements in the fourth quarter of 2019. Income from the upfront
and any future payments will be reported within Other Operating
Income & Expense. In 2018, Arimidex had sales of $37m in the
countries covered by this agreement, while Casodex had sales of
$24m. The divestment does not change the Company's financial
guidance for 2019.
About Arimidex
Arimidex (anastrozole) is an aromatase inhibitor, indicated
primarily for the adjuvant treatment of postmenopausal women with
hormone receptor-positive early breast cancer, the first-line
treatment of postmenopausal women with hormone receptor-positive or
hormone receptor-unknown locally advanced or metastatic breast
cancer and the treatment of advanced breast cancer in
postmenopausal women with disease progression, following tamoxifen
therapy.
About Casodex
Casodex (bicalutamide) is an androgen-receptor inhibitor,
indicated for use in combination therapy with a luteinising
hormone-releasing hormone analogue for the treatment of Stage D2
metastatic carcinoma of the prostate.
About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. Please visit
astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Media Relations
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharmaceuticals (Cardiovascular, Metabolism) +44 203 749 5711
BioPharmaceuticals (Renal) Environmental, Social and
Nick Stone Governance +44 203 749 5716
BioPharmaceuticals (Respiratory)
Josie Afolabi Other medicines +44 203 749 5631
Finance
Craig Marks Fixed income +44 7881 615 764
Corporate access
Jennifer Kretzmann Retail investors +44 203 749 5824
US toll-free +1 866 381 72 77
References
1. For Arimidex and Casodex: Albania, Austria, Belgium,
Bulgaria, Croatia, Cyprus, Estonia, Finland, France, France
exports(2) , Germany, Greece, Ireland, Israel, Italy,
Liechtenstein, Luxembourg, Monaco, the Netherlands, Norway,
Romania, Serbia, Slovenia, Spain, Sweden, Switzerland, Algeria,
Morocco, Lebanon, Tunisia, Turkey, and French-speaking Africa
(Ivory Coast, Benin, Gabon, Niger, Mauritania, Burkina Faso, Mali,
Chad, Burundi, Cameroon, Guinea, Senegal, Central African Republic,
Togo, Djibouti, Democratic Republic of the Congo, Republic of the
Congo and Madagascar). Additionally, for Arimidex: Czech Republic,
Hungary, Lithuania, Malta, Poland and Portugal.
2. France exports are sales made in France, under the French
entity of AstraZeneca, for export to French DOM-TOMs (Départements
d'outre-mer, Territoires d'outre-mer): DOM-TOMs are either
'overseas collectives' (administrative divisions of France) or
'overseas departments' (officially part of France), and include:
French Guyana, French Polynesia, Guadeloupe, Mayotte, Martinique,
New Caledonia, La Reunion, Saint-Barthelemy, Saint-Martin,
Saint-Pierre-et-Miquelon and Wallis-et-Futuna.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCQBLBLKLFXFBF
(END) Dow Jones Newswires
December 20, 2019 02:00 ET (07:00 GMT)
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024
